language_icon
EN
HI

Astec Lifesciences Share price

ASTEC

720.8

13.60 (-1.85%)
NSE
BSE
Last updated on 24 Apr, 2026 | 15:31 IST
Today's High

739.85

Today's Low

705.85

52 Week Low

513.40

52 Week High

988.51

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Astec Lifesciences Chart

Astec Lifesciences Share Key Metrics

Volume
39157.00
Market Cap
1606.10 CR
LTQ@LTP
1@720.80
ATP
718.75
Var Margin
50 %
Circuit Range
587.55-881.25
Delivery %
38.67 %
Value
2.81 CR
ASM/GSM
No
Market Lot
1

Summary

Astec Lifesciences share price stands at ₹720.8 at 24 Apr, 2026 | 15:31. The stock Astec Lifesciences intraday movement has stayed between ₹705.85 and ₹739.85, while on a 52-week basis it has fluctuated from ₹513.40 to ₹988.51.
In terms of trading activity, Astec Lifesciences has recorded a volume of 39157 shares. The Astec Lifesciences has a market cap of ₹22282238. The stock’s Average Traded Price (ATP) stands at ₹71875, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1, 72080.
The Astec Lifesciences operates within a circuit range of ₹587.55-881.25 – ₹587.55-881.25, with a Value of ₹2.81 CR. The Delivery Percentage for the day is 38.67%. Additionally, Astec Lifesciences currently falls under the No framework, and trades with a market lot size of 1.

Astec Lifesciences Fundamentals

View More
P/E Ratio

0

P/B Ratio

4.04

Div. Yield

0

Sector P/E

39.02

Sector P/B

2.21

Sec. Div. Yield

0.34

Astec Lifesciences Resistance and Support

Pivot 737.53

Resistance

First Resistance

747.36

Second Resistance

760.33

Third Resistance

770.16

Support

First Support

724.56

Second Support

714.73

Third Support

701.76

Astec Lifesciences Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

66.75%

Mutual Fund

4%

Insurance

0%

Foreign Institutional Investors

1.2%

Domestic Institutional Investors

0.63%

Retail

27.42%

Others

0%

Total Promoters
MAR '24
66.75%
JUN '24
66.75%
SEP '24
66.75%
DEC '24
66.75%

Astec Lifesciences Corporate Actions

DateAgenda
2026-04-27Audited Results
2026-01-30Quarterly Results
2025-10-29Quarterly Results
2025-07-28Quarterly Results
2025-06-30Right Issue of Equity Shares
2025-06-24Others
2025-04-23Audited Results
2025-01-27Quarterly Results

Astec Lifesciences News

Astec LifeSciences Limited

Astec Lifesciences Limited will hold a board meeting on April 27, 2026, to consider and approve its audited yearly standalone and cons. financial results for the fiscal year ended March 31, 2026. The trading window for the company's shares is closed from April 1 to April 29, 2026.
Apr 17 2026 22:04:00

Astec LifeSciences Limited

Astec Lifesciences Limited will hold a board meeting on April 27, 2026, to consider and approve its audited yearly standalone and cons. financial results for the fiscal year ended March 31, 2026. The trading window for the company's shares is closed from April 1 to April 29, 2026.
Apr 17 2026 22:04:00

Astec LifeSciences Limited

Astec Lifesciences Limited will hold a board meeting on April 27, 2026, to consider and approve its audited yearly standalone and cons. financial results for the fiscal year ended March 31, 2026. The trading window for the company's shares is closed from April 1 to April 29, 2026.
Apr 17 2026 22:04:00

Astec Lifesciences Ltd - 533138 - Board Meeting Intimation for Approval Of Financial Results

Astec LifeSciences board to meet on April 27, 2026, to consider and approve the standalone and consolidated audited financial results for Q4 FY26 and the financial year ended March 31, 2026. These results will be reviewed by the Audit Committee prior to the board meeting.
Apr 17 2026 22:04:00

Astec LifeSciences Limited

Astec LifeSciences board is scheduled to meet on April 27, 2026. The meeting will consider and approve the standalone and consolidated audited financial results for Q4 and FY26, after review by the Audit Committee.
Apr 17 2026 21:04:00

Astec LifeSciences Limited

Astec LifeSciences confirmed timely payment of ₹25 crore for its Commercial Paper, Astec-CP-188, ensuring compliance with its financial obligations. The payment was made on the maturity date of April 15, 2026.
Apr 15 2026 18:04:00

Astec LifeSciences Limited

Astec LifeSciences announced significant management changes. Burjis Godrej transitioned from his role as Managing Director to an Additional Director Non Executive, effective April 13, 2026. Concurrently, Arijit Mukherjee, the Chief Operating Officer, was formally appointed to his role, strengthening the operational leadership.
Apr 15 2026 15:04:00

Astec LifeSciences Limited

Astec LifeSciences board approved significant leadership changes. Nadir Godrej retired as Chairman, while Vishal Sharma was appointed as the new Chairman. Burjis N. Godrej resigned as MD but was re-appointed as Non-Executive Director, alongside new appointments Mathew Eipe and Arijit Mukherjee.
Apr 13 2026 21:04:00

Astec LifeSciences Limited

Astec LifeSciences board approved significant leadership changes. Nadir Godrej retired as Chairman, while Vishal Sharma was appointed as the new Chairman. Burjis N. Godrej resigned as MD but was re-appointed as Non-Executive Director, alongside new appointments Mathew Eipe and Arijit Mukherjee.
Apr 13 2026 21:04:00

Astec LifeSciences Limited

Astec LifeSciences announced significant board changes effective April 13, 2026, including Nadir Godrej's retirement as Chairperson and the appointment of Vishal Sharma to lead the board. Burjis N. Godrej stepped down as MD but will continue as a Non-Executive Director, alongside Arijit Mukherjee's new role as Executive Director & COO, pending shareholder approval.
Apr 13 2026 18:04:00
Read More

About Astec Lifesciences

NSE : 17728  
BSE : 533138  
ISIN : INE563J01010  

Our Company was incorporated on January 25 1994 under the Companies Act 1956 as UrshilaTraders Private Limited. Our Company was originally promoted by Mrs. Reena Bagai and Mrs.Avita Fernandes. Their shareholding was purchased by Mr. Ashok V Hiremath and Mr. PratapGarud on February 11 1994. The name of our Company was changed to Astec Chemicals PrivateLimited on August 19 1994 and further to Astec LifeSciences Private Limited on March 3 2006.With effect from April 27 2006 Astec LifeSciences Private Limited was converted into a publiclimited company under the name of "Astec LifeSciences Limited".We carry out our manufacturing activities at two locations in Maharashtra India comprising ofthree units in Maharashtra viz. one unit at Dombivli and two units at Mahad (Unit 1 and Unit 2).We started our first manufacturing unit in August 1994 by acquiring a sick unit in DombivliMaharashtra having an installed capacity of 120 MT for the manufacture of Dicap apharmaceutical intermediate.With a view to expand our operations we entered into an agreement with Behram ChemicalsPrivate Limited on February 18 2002 for using and operating their manufacturing facilities locatedat B-16 Mahad Industrial Area Sub-District Mahad District Raigad Maharashtra. BehramChemicals Private Limited was engaged in manufacture of chemicals and pesticides having aninstalled capacity of 130 MT.Behram Chemicals Private Limited was initially promoted by Mr. Jehangir J. Mistry Mrs. Villoo J.Mistry Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma in April 1993. During August 1998further shares were allotted to M.C. Chemicals and some members of Gangani family viz. Mr.Nasrudin K Gangani Mr. S. N. Gangani Mrs. N. N. Gangani Mr. T. K. Gangani and Khoja BoneMills Private Limited (a company promoted by Gangani family). Looking at the potential inBehram Chemicals Private Limited our Company have acquired 65.63% share by entering intoShare Purchase Agreement with the above members of Gangani family on April 2 2007. Mr.Jehangir J. Mistry Mrs. Villoo J. Mistry Mrs. Kamla G. Sippy and Mr. Surinder Kumar VermaM.C. Chemicals and Gangani family are not related to our Promoters / our Directors in anymanner in any capacity whatsoever. With this acquisition Behram Chemicals Private Limitedbecame a subsidiary of our Company. During 2003-04 we expanded total installed capacity of our units (Dombivli and Mahad) from 250MT to 500 MT. We renewed the agreement on August 1 2004 for a further period of 66 monthsending on January 31 2010. For more details in respect of the current agreement.In 2004 we acquired a plot located at B-17 Mahad Maharashtra and set up a new manufacturingfacility as an Export Oriented Unit (EOU) in the year 2005 (as Unit 2) which is located adjacent toUnit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2 our total installedcapacity increased to 1500 MT. We further expanded our total capacities to 2000 MT during 2006-07 and to 2500 MT during 2007-08.Our Company is primarily involved in the production of active ingredients and intermediates foragrochemicals and pharmaceutical segment. Hexaconazole Tebuconazole Metalaxyl andPropiconazole are some of our key products in agrochemical segment which are generally used incrop protection and Dicap is one of our key Pharmaceutical intermediate which is used inmanufacture of antifungal agents. Triazole fungicides which includes HexaconazoleTebuconazole and Propiconazole is one of our major product in the agrochemical segment andhas contributed 63.67% to our total sales whereas Dicap a key product in pharmaceutical segmenthas contributed 9.01% during FY 2007-08.Major events of our CompanyPeriod EventsJanuary 1994 Incorporation of Urshila Traders Private LimitedAugust 1994 Change of name to Astec Chemicals Private LimitedAugust 1994 Commenced first manufacturing unit at Dombivli MaharashtraMay 2001 Certified ISO 9002 by International Standards Certification Pty Limited AustraliaFebruary 2002 Entered into an agreement with Behram Chemicals Private LimitedMarch 2005 Re-certified ISO 9001:2000 by International Standards Certification Pty Limited AustraliaMay 2005 Commenced another manufacturing unit (Unit 2) as Export Oriented Unit at Mahad MaharashtraMarch 2006 Change of name to Astec LifeSciences Private LimitedApril 2006 Conversion of our Company from a private limited company to a public limited company January 2007 Established Astec Europe in Tournai BelgiumApril 2007 Behram Chemicals Private Limited became our subsidiary by acquisition of 65.63% vide Share Purchase Agreement dated April 2 2007

Read More

Astec Lifesciences Management

NamePosition
Tejashree PradhanCompany Secretary & Compliance Officer
Nadir B GodrejChairman
View More

Astec Lifesciences FAQs

The Buying Price of Astec Lifesciences share is 720.8 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Astec Lifesciences stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Astec Lifesciences, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Astec Lifesciences shares is 0. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Astec Lifesciences shares is 4.04. Useful to assess the stock's value relative to its book value.

To assess Astec Lifesciences’s valuation compare Sector P/E, P/B which are 39.02 & 2.21 with sector averages, along with growth rates and financial metrics.

The Market Cap of Astec Lifesciences is 1606.10 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Astec Lifesciences share price is 988.51 & 513.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Astec Lifesciences belongs to the Chemicals sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost